Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Is it prime-time for CAR-T in myeloma?

Nina Shah • 7 Dec 2019
ASH 2019
Multiple Myeloma CAR-T

Nina Shah, MD, University of California-San Francisco, San Francisco, CA, gives an overview of the CAR T-cell therapy landscape in multiple myeloma (MM) and what we can expect to see in the future. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Nina Shah

19:39
T-Cell Engagers: targets, challenges and opportunity
Hermann Einsele et al. • 27 Mar 2022
1:28
NKTR-255 in multiple myeloma and NHL
Nina Shah • 10 Dec 2021
2:15
Reporting patient experiences during the KarMMa trial
Nina Shah • 10 Dec 2021
2:06
Subanalysis of the KarMMa Trial: Predicting complete response to CAR-T in multiple myeloma
Nina Shah • 10 Dec 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals